MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer
NCT03300817
Site status not listed — check the official record
- Conditions
- Lung Carcinoma
- Interventions
- Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Pittsburgh, Pennsylvania